Wall Street analysts expect Hologic (HOLX) to post quarterly earnings of $1.09 per share in its upcoming report, which indicates a year-over-year increase of 5.8%. Revenues are expected to be $1.07 billion, up 4.9% from the year-ago quarter.
The current level reflects an upward revision of 0.6% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Hologic metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Revenues- GYN surgical' will likely reach $180.97 million. The estimate indicates a year-over-year change of +8.8%.
It is projected by analysts that the 'Revenues- Diagnostics- Molecular diagnostics' will reach $354.66 million. The estimate indicates a year-over-year change of +4%.
The consensus estimate for 'Revenues- Diagnostics- Blood screening' stands at $4.77 million. The estimate indicates a year-over-year change of +16.3%.
The average prediction of analysts places 'Revenues- Breast health- Breast imaging' at $294.22 million. The estimate indicates a change of +4.5% from the prior-year quarter.
Analysts expect 'Revenues- Total Diagnostics' to come in at $479.84 million. The estimate points to a change of +2% from the year-ago quarter.
Analysts forecast 'Revenues- Skeletal health' to reach $20.13 million. The estimate indicates a year-over-year change of +27.4%.
Analysts' assessment points toward 'Revenues- Diagnostics- Cytology and perinatal' reaching $120.41 million. The estimate points to a change of -4% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Total Breast health' should come in at $392.22 million. The estimate indicates a year-over-year change of +6.3%.
The collective assessment of analysts points to an estimated 'Revenues- Breast health- Interventional breast solutions' of $98.00 million. The estimate indicates a change of +12% from the prior-year quarter.
Analysts predict that the 'Revenues- Service and other' will reach $212.72 million. The estimate indicates a change of +4.3% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product' will reach $860.93 million. The estimate indicates a change of +5.3% from the prior-year quarter.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have experienced a change of +0.7% in the past month compared to the +0.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HOLX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
